Abstract

Tγδ and B1 lymphocytes are essential components of the mucosal immune system, activated directly by different bacterial and viral ligands without additional costimulatory signals and preprocessing of other immune effectors. This ability enables the immune system to provide rapid protection against pathogens and contributes to the decoding mechanism of the sensitizing activity of mucosal antigens. The early interaction of these cells results in the production of antibodies of immunoglobulin M (IgM) and IgA isotypes, but not immunoglobulin E (IgE). We studied the subcutaneous, intranasal, and oral delivery as three major routes of potential entry for antigens of opportunistic microorganisms, using the immunomodulator Immunovac-VP-4, which is able to activate Tγδ and B1 lymphocytes. The subcutaneous and intranasal routes produced a significant increase of these cells in lymph nodes associated with the nasal cavity (NALT) and in those associated with bronchial tissue (BALT). The oral route significantly increased levels of these cells in the spleen, in NALT, BALT, and in nodes associated with the gut (GALT). We found that mucosal application of Immunovac-VP-4, which contains antigens of conditionally pathogenic microorganisms, in conjunction with the activation of Tγδ and B1, induces adaptive immune mechanisms not only in the lymphoid formations associated with the respiratory system and with GALT, but also in the spleen [increased expression of cluster of differentiation 3 (CD3), CD4, CD8, CD19, and CD25]. This indicates that there is migration of lymphoid cells from the regional lymph nodes and mucosal lymphoid tissues via the lymph and blood to distant organs, resulting in lymphoid development, and both local and systemic immunity. Mucosal application of Immunovac-VP-4 in mice potentiates the cytotoxic activity of NK cells in the NALT, BALT, and GALT. The highest cytotoxicity was observed in cells, derived from lymphoid tissue of the intestine after oral immunization. Although we found that cytokine production was increased by all three immunization routes, it was most intensive after subcutaneous injection. Our findings confirm that there is an intensive exchange of lymphocytes not only between lymphoid formations in the mucous membranes of the respiratory tract and of GALT, but also with the spleen, which means that if effective mucosal vaccines are developed, they can induce both local and systemic immunity.

Highlights

  • Theoretical and experimental studies have shown that the main components of the mucosal immune system (MIS), determining the particular features of functional activity, are Tγδ lymphocytes and B1 cells in the epithelial mucosa, which have the ability to detect pathogen-associated molecular patterns (PAMPs) without costimulator signals and preliminary processing by other effectors cells [1,2,3,4]

  • The spleens, lymph nodes associated with the nasal cavity (NALT), nodes associated with bronchial tissue (BALT), and nodes associated with the gut (GALT) were analyzed and the number and phenotype of mononuclear cells expressing Toll-like receptors (TLRs) in the immunized mice were determined

  • The levels of TLR2, TLR4, and TLR9 in the NALT–BALT increased after subcutaneous vaccine administration

Read more

Summary

Introduction

Theoretical and experimental studies have shown that the main components of the mucosal immune system (MIS), determining the particular features of functional activity, are Tγδ lymphocytes and B1 cells in the epithelial mucosa, which have the ability to detect pathogen-associated molecular patterns (PAMPs) without costimulator signals and preliminary processing by other effectors cells [1,2,3,4]. Pattern-recognition receptors, Toll-like receptors (TLRs) recognize PAMPs of various pathogen classes, interact with cellular adaptive systems, and trigger the cascade of various signaling pathways to induce the complex of protective reactions [6,7,8]. The importance of such studies is obvious, yet the molecular and cellular mechanisms of innate and adaptive immunity activation in response to mucosal application of immunomodulators and vaccines have not been well investigated. Various experimental models have shown the immunostimulatory effects of Immunovac-VP4 [9, 10]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call